BRPI0515115A - método de tratar uma doença de pele proliferativa - Google Patents

método de tratar uma doença de pele proliferativa

Info

Publication number
BRPI0515115A
BRPI0515115A BRPI0515115-5A BRPI0515115A BRPI0515115A BR PI0515115 A BRPI0515115 A BR PI0515115A BR PI0515115 A BRPI0515115 A BR PI0515115A BR PI0515115 A BRPI0515115 A BR PI0515115A
Authority
BR
Brazil
Prior art keywords
treating
skin disease
proliferative skin
proliferative
administering
Prior art date
Application number
BRPI0515115-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Samuel R Denmeade
Robert L Hudkins
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of BRPI0515115A publication Critical patent/BRPI0515115A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0515115-5A 2004-09-10 2005-09-09 método de tratar uma doença de pele proliferativa BRPI0515115A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60920304P 2004-09-10 2004-09-10
US11/222,409 US20060058250A1 (en) 2004-09-10 2005-09-08 Methods of treating proliferative skin diseases using carbazole derivatives
PCT/US2005/032489 WO2006031772A1 (en) 2004-09-10 2005-09-09 Methods of treating proliferative skin diseases using carbazole derivatives

Publications (1)

Publication Number Publication Date
BRPI0515115A true BRPI0515115A (pt) 2008-07-01

Family

ID=36034857

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515115-5A BRPI0515115A (pt) 2004-09-10 2005-09-09 método de tratar uma doença de pele proliferativa

Country Status (14)

Country Link
US (1) US20060058250A1 (https=)
EP (1) EP1786418A1 (https=)
JP (1) JP2008512497A (https=)
KR (1) KR20070113186A (https=)
AR (1) AR050930A1 (https=)
AU (1) AU2005285007A1 (https=)
BR (1) BRPI0515115A (https=)
CA (1) CA2577024A1 (https=)
IL (1) IL181003A0 (https=)
MX (1) MX2007002532A (https=)
MY (1) MY156431A (https=)
NO (1) NO20071052L (https=)
TW (1) TW200621266A (https=)
WO (1) WO2006031772A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR114110A1 (es) 2018-02-28 2020-07-22 Lilly Co Eli Anticuerpo anti-trka
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
DK1044203T3 (da) * 1997-12-31 2003-07-14 Cephalon Inc 3'-epimere K-252a-derivater
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6013646A (en) * 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US6841567B1 (en) * 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6399780B1 (en) * 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
EP1309721A2 (en) * 2000-08-11 2003-05-14 Cephalon, Inc. Modulating multiple lineage kinase proteins
US6667173B2 (en) * 2000-12-01 2003-12-23 The Schepens Eye Research Institute Nucleic acids encoding platelet derived growth factor-alpha receptors
US7241779B2 (en) * 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles

Also Published As

Publication number Publication date
JP2008512497A (ja) 2008-04-24
MX2007002532A (es) 2007-05-09
EP1786418A1 (en) 2007-05-23
AR050930A1 (es) 2006-12-06
IL181003A0 (en) 2007-07-04
TW200621266A (en) 2006-07-01
AU2005285007A1 (en) 2006-03-23
KR20070113186A (ko) 2007-11-28
WO2006031772A1 (en) 2006-03-23
US20060058250A1 (en) 2006-03-16
NO20071052L (no) 2007-04-03
MY156431A (en) 2016-02-26
CA2577024A1 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
CY1122134T1 (el) Συνθεση για χρηση στη θεραπευτικη αντιμετωπιση της γαστρεντερικης δυσκινησιας
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
GT201100181A (es) "inhibidores de proteina cinasa"
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
EA201370208A1 (ru) Формы рифаксимина и их применение
CY1109877T1 (el) Αντισωματα εναντι αμυλοειδους-βητα πεπτιδιου
NO20083885L (no) Fremgangsmate for behandling av inflammatoriske sykdommer
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BRPI0510094A (pt) uso de flibanserina no tratamento pré-menstrual e outros distúrbios sexuais femininos
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
MX341883B (es) Composicion farmaceutica para el tratamiento y prevencion de canceres.
MX374396B (es) Rocio de fentanilo sublingual.
EA201490994A1 (ru) Функционально-модифицированные олигонуклеотиды и их субъединицы
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
EA201070740A1 (ru) Способ лечения перелома кости антителами против склеростина
DK1933833T3 (da) Terapi til behandling af overaktiv blære
CY1115690T1 (el) Συνθεσεις βασιζομενες σε arthrospirα και χρησεις αυτων
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
BRPI0906094B8 (pt) composto
EA201170356A1 (ru) Полиморфные и аморфные формы лакозамида и аморфные композиции
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
AU2010279892A8 (en) Humanized anti-amyloid-b oligomer antibody
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
GT200500127A (es) Composiciones y metodos para el tratamiento de trastorno disforico premenstrual

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.